Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
Dongyue Li, Peng Zhan, Huiqing Liu, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Xinyong Liu
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Shandong University, 44, West Culture Road, 250012 Jinan, Shandong, PR China.
Bioorganic & medicinal chemistry 2013 Apr 1In continuation of our efforts toward identification and optimization of novel non-nucleoside reverse transcriptase inhibitors (NNRTIs), we have employed a structure-based bioisosterism strategy, with which a new series of diarylpyridazine (DAPD) derivatives were synthesized and evaluated for their anti-HIV-1 (human immunodeficiency virus type 1) activity. Most of the title compounds displayed excellent anti-HIV-1 activity at submicromolar concentrations ranging from 34 nM to 5.08 μM. The most promising compound 8g inhibited HIV-1 IIIB in MT-4 cells at a low EC50 value (0.034 μM), which was lower than the reference drug nevirapine and delavirdine. The structure activity relationships (SARs) were discussed and rationalized by docking simulations. Copyright © 2013 Elsevier Ltd. All rights reserved.
Citation
Dongyue Li, Peng Zhan, Huiqing Liu, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Xinyong Liu. Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs. Bioorganic & medicinal chemistry. 2013 Apr 1;21(7):2128-34
Mesh Tags
Substances
PMID: 23415090
View Full Text
